Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP

- Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticated financial institutions, family offices, and leading multinational corporations (strategic investors). PVP III LP's strategic investors include a who's who of market leaders around the world in their respective industries, including Pfizer Inc. (NYSE: PFE), Corning Incorporated (NYSE:GLW), W. L. Gore & Associates, Showa Denko K. K. (TYO:4004), Nissan Chemical Corporation (TYO:4021), Nagase & Co., Ltd. (TYO:8012), and LG Technology Ventures, which is the investment vehicle of LG Chem, Ltd. (KRX: 051910).

As the leading venture capital firm focused on Advanced Materials and Device investing, PVP has an established track record of strong returns and is known by entrepreneurs and corporations globally. PVP also has a reputation for forging deep partnerships with its strategic investors working closely with them on open innovation to identify attractive market opportunities. Building off the success of its first two funds, PVP III LP will continue to focus on investing in start-ups developing breakthrough Advanced Materials and Device innovations while expanding its presence globally.

Dr. John T. Chen , Managing General Partner of PVP, commented, "We are pleased by the strong interest in PVP III LP from new investors and continued support from our existing LPs and are happy to have closed the new fund despite the current global challenges."

Dr. Zachariah Jonasson , Managing General Partner of PVP added, "We are excited to be working with both the most innovative multinational corporations and entrepreneurs globally."

About Phoenix Venture Partners LLC

Phoenix Venture Partners LLC is a leading venture capital firm that invests in and partners with outstanding entrepreneurs to commercialize breakthrough Advanced Materials and Device innovations. PVP's team has an unparalleled track record of founding, building and investing in successful Advanced Materials start-ups across multiple industries. The firm's investment strategy is flexible and predicated on assisting entrepreneurs with customer and supply chain partnerships, business development, as well as with strategic and operational support. PVP collaborates with a select ecosystem of forward-looking global corporations on business development and open innovation interests. PVP is based in the Silicon Valley with a satellite office in Seattle , WA.  For additional information please visit our website at www.phoenix-vp.com or email us at information@phoenix-vp.com .

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/phoenix-venture-partners-llc-raises-3rd-fund-pvp-iii-lp-301214652.html

SOURCE Phoenix Venture Partners, LLC.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News